Matsumoto Yukihiro, Dogru Murat, Goto Eiki, Ishida Reiko, Kojima Takashi, Onguchi Tatsuya, Yagi Yukiko, Shimazaki Jun, Tsubota Kazuo
Department of Ophthalmology, Tokyo Dental College, Chiba, Japan.
Cornea. 2006 Jul;25(6):644-50. doi: 10.1097/01.ico.0000208822.70732.25.
To evaluate the safety and efficacy of an original warm moist air device on tear functions and ocular surface of patients with simple meibomian gland dysfunction (MGD).
Fifteen patients with simple MGD and 20 healthy volunteers were recruited in an initial prospective interventional clinical trial to evaluate the safety and short-term effects of the warm moist air device. The device was applied to the eyes of the subjects for 10 minutes. Temperatures of the eye lids and corneas were measured with an infrared thermometer. Symptoms of ocular fatigue were scored using visual analog scales (VASs). Schirmer test, tear film break-up time (BUT), DR-1 tear film lipid layer interferometry, fluorescein staining, and rose bengal staining were also performed before and after the application of the eye steamer. After the initial study, another 2-week prospective clinical trial was carried out in 10 patients with MGD who received the warm moist air treatment. Ten other patients were also recruited and received warm compress treatment with hot towels for 2 weeks to evaluate the long-term effects of the warm moist air device and the warm compresses on tear film lipid layer thickness and ocular surface health. The warm moist air device and the warm compresses were applied for 10 minutes twice a day. The changes in VAS scores for symptoms, BUT values, fluorescein, and rose bengal staining scores were examined before and after each treatment during the second trial.
VAS scores of ocular fatigue improved significantly with short- and long-term applications of the warm moist air device in both studies. The mean corneal surface and eye lid temperatures showed significant elevation within safe limits 10 minutes after the moist air application. The mean BUT prolonged significantly in the patients receiving warm moist air applications but did not change significantly in those treated with warm compresses. DR-1 tear film lipid layer interference showed evidence of lipid expression in the patients and controls, with thickening of the tear film lipid layer after 10 minutes of warm moist air device use. In the 2-week trial, tear film lipid layer thickness increased in both warm moist air device and warm compress groups, with a greater extent of increase in the warm moist air device group.
Warm moist air device use provided symptomatic relief of ocular fatigue and improvement of tear stability in patients with MGD. The new warm moist air device seems to be a safe and promising alternative in the treatment of MGD.
评估一种新型温热湿空气装置对单纯睑板腺功能障碍(MGD)患者泪液功能和眼表的安全性及有效性。
在一项初始前瞻性干预性临床试验中招募了15例单纯MGD患者和20名健康志愿者,以评估温热湿空气装置的安全性和短期效果。该装置应用于受试者眼部10分钟。用红外温度计测量眼睑和角膜的温度。使用视觉模拟量表(VAS)对眼疲劳症状进行评分。在使用眼部熏蒸器前后还进行了泪液分泌试验、泪膜破裂时间(BUT)、DR-1泪膜脂质层干涉测量、荧光素染色和孟加拉玫瑰红染色。在初始研究之后,对10例接受温热湿空气治疗的MGD患者进行了另一项为期2周的前瞻性临床试验。还招募了另外10例患者,用热毛巾进行热敷治疗2周,以评估温热湿空气装置和热敷对泪膜脂质层厚度和眼表健康的长期影响。温热湿空气装置和热敷均每天应用2次,每次10分钟。在第二项试验中,在每次治疗前后检查症状的VAS评分、BUT值、荧光素和孟加拉玫瑰红染色评分的变化。
在两项研究中,短期和长期应用温热湿空气装置后,眼疲劳的VAS评分均显著改善。在应用湿空气10分钟后,平均角膜表面和眼睑温度在安全范围内显著升高。接受温热湿空气治疗的患者平均BUT显著延长,而接受热敷治疗的患者平均BUT无显著变化。DR-1泪膜脂质层干涉显示患者和对照组均有脂质表达,使用温热湿空气装置10分钟后泪膜脂质层增厚。在为期2周的试验中,温热湿空气装置组和热敷组的泪膜脂质层厚度均增加,温热湿空气装置组增加幅度更大。
使用温热湿空气装置可缓解MGD患者的眼疲劳症状并改善泪液稳定性。这种新型温热湿空气装置似乎是治疗MGD的一种安全且有前景的替代方法。